Program
AB-101
Also written as “zabalafin”.
Its studies are mostly in Hepatitis B, Chronic · Lymphoma, Non-Hodgkin · Lupus Nephritis · Hodgkin Disease · Dermatitis, Atopic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Artiva Biotherapeutics | 21 open or running | phase 2since Dec 4, 2020 | Dec 4, 2020 | Aug 2027phase 1 · NCT06265220 |
| Affimed | 10 open or running | phase 2since May 19, 2023 | May 19, 2023 | none ahead |
| Alphyn Biologics | 11 open or running | phase 2since Feb 27, 2025 | Feb 27, 2025 | none ahead |
| Applied Biology | 10 open or running | early phase 1since Jul 8, 2018 | Jul 8, 2018 | none ahead |
| Arbutus Biopharma | 10 open or running | phase 1since Jul 14, 2023 | Jul 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2018First study: early phase 1 study in Sexual Dysfunction, PhysiologicalNew to Applied BiologyApplied Biology · NCT03592121 · 3 enrolled · United States
- Dec 4, 2020Artiva Biotherapeutics's first study: phase 2 study in Lymphoma, Non-HodgkinNew to Artiva BiotherapeuticsArtiva Biotherapeutics · NCT04673617 · 45 enrolled · United States
- May 19, 2023Affimed's first study: phase 2 study in RecurrenceNew to AffimedAffimed · NCT05883449 · 25 enrolled · United States
- Jul 14, 2023Arbutus Biopharma's first study: phase 1 study in Hepatitis B, ChronicNew to Arbutus BiopharmaArbutus Biopharma · NCT05960240 · 128 enrolled · Hong Kong, Italy, Moldova and more
- Feb 9, 2024Phase 1 study in Lupus Erythematosus, SystemicArtiva Biotherapeutics · NCT06265220 · 51 enrolled · United States
- Feb 27, 2025Alphyn Biologics's first study: phase 2 study in Dermatitis, AtopicNew to Alphyn BiologicsAlphyn Biologics · NCT06855745 · 72 planned · Australia
Ahead
- Aug 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicArtiva Biotherapeutics · NCT06265220
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06855745Dermatitis, Atopic · Australia | 2 | Recruiting | Alphyn Biologics | Oct 30, 2025 | 72 |
| NCT06265220Lupus Erythematosus, Systemic · United States | 1 | Active, not recruiting | Artiva Biotherapeutics | Aug 2027 | 51 |
| NCT05960240Hepatitis B, Chronic · Hong Kong, Italy, Moldova and more | 1 | Completed | Arbutus Biopharma | Dec 4, 2025 | 128 |
| NCT05883449Recurrence · United States | 2 | Terminated | Affimed | Nov 7, 2024 | 25 |
| NCT04673617Lymphoma, Non-Hodgkin · United States | 2 | Completed | Artiva Biotherapeutics | Oct 6, 2025 | 45 |
| NCT03592121Sexual Dysfunction, Physiological · United States | Early 1 | Completed | Applied Biology | Oct 12, 2019 | 3 |
How it is read
Names in the registry
- “AB-101”, 5 entries
- “zabalafin”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Lupus Nephritis, 1 study
- Hodgkin Disease, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.